VCYT vs EXAS vs NTRA vs CDNA vs ACNB

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 13. 8% for CareDx, Inc (CDNA). ACNB Corporation (ACNB) offers the better valuation at 14. 7x trailing P/E (9. 9x forward), making it the more compelling value choice. Analysts rate Veracyte, Inc. (VCYT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACNB Corporation (ACNB) is the cheapest at 14.

7x versus Veracyte, Inc. at 49. 7x. On forward P/E, ACNB Corporation is actually cheaper at 9. 9x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -72. 4% for CareDx, Inc (CDNA). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus ACNB's +188. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus Veracyte, Inc. 's 1. 52β — meaning VCYT is approximately 1158% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Veracyte, Inc. (VCYT) carries a lower debt/equity ratio of 3% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 13. 8% for CareDx, Inc (CDNA). On earnings-per-share growth, the picture is similar: Veracyte, Inc. grew EPS 164. 5% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACNB Corporation (ACNB) is the more profitable company, earning 21.

7% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 21. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACNB leads at 27. 3% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — ACNB leads at 73. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACNB Corporation (ACNB) trades at 9.

9x forward P/E versus 582. 8x for Exact Sciences Corporation — 572. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NTRA: 19. 4% to $262. 50.

In this comparison, ACNB (2.

6% yield) pays a dividend. VCYT, EXAS, NTRA, CDNA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VCYT (Healthcare) and EXAS (Healthcare) and NTRA (Healthcare) and CDNA (Healthcare) and ACNB (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VCYT is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; NTRA is a mid-cap high-growth stock; CDNA is a small-cap quality compounder stock; ACNB is a small-cap high-growth stock. ACNB pays a dividend while VCYT, EXAS, NTRA, CDNA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.